Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement (Q33997625)

30 July 2017

title

Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement (English)

1 reference

30 July 2017

author

Joachim Müller-Quernheim

object named as

Joachim Müller-Quernheim

1 reference

30 July 2017

Ulrich Costabel

1 reference

30 July 2017

0 references

Elliot S Barnathan

1 reference

30 July 2017

Robert P Baughman

1 reference

30 July 2017

Marjolein Drent

1 reference

30 July 2017

Mani Kavuru

1 reference

30 July 2017

Marc A Judson

1 reference

30 July 2017

Susan Flavin

1 reference

30 July 2017

Roland du Bois

1 reference

30 July 2017

Carlo Albera

1 reference

30 July 2017

Martin Brutsche

1 reference

30 July 2017

Gerald Davis

1 reference

30 July 2017

James F Donohue

1 reference

30 July 2017

Rozsa Schlenker-Herceg

1 reference

30 July 2017

Kim Hung Lo

1 reference

30 July 2017

Barry Oemar

1 reference

30 July 2017

Sarcoidosis Investigators

1 reference

30 July 2017

language of work or name

English

0 references

publication date

13 July 2006

1 reference

American Journal of Respiratory and Critical Care Medicine

30 July 2017

published in

1 reference

30 July 2017

volume

174

1 reference

30 July 2017

1 reference

30 July 2017

page(s)

795-802

1 reference

A case control etiologic study of sarcoidosis: environmental and occupational risk factors

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Future directions in sarcoidosis research: summary of an NHLBI working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Treatment of sarcoidosis with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Corticosteroid therapy in pulmonary sarcoidosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Serum Angiotensin-Converting Enzyme Activity in Evaluating the Clinical Course of Sarcoidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Cutaneous complications in immunosuppressed renal homograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Epithelioid sarcoma: the clinicopathological complexities of this rare soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Regional treatment of metastasis: role of regional perfusion. State of the art isolated limb perfusion for limb salvage

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Growth inhibition in clonal subpopulations of a human epithelioid sarcoma cell line by retinoic acid and tumour necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Increased risk for cancer following sarcoidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Sarcoidosis and cancer revisited: a long-term follow-up study of 555 Danish sarcoidosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

21 January 2018

Statement on Sarcoidosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Fungal infections as a complication of therapy for sarcoidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Review article: safety of infliximab in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

Interferon-γ1b Therapy in Idiopathic Pulmonary Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-402OC

10.1164/RCCM.200603-402OC

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference